Klaus Cichutek (born 26 February 1956 in

Recklinghausen Recklinghausen (; Westphalian: ''Riäkelhusen'') is the northernmost city in the Ruhr-Area and the capital of the Recklinghausen district. It borders the rural Münsterland and is characterized by large fields and farms in the north and indus ...

) is a German biochemist and the current President of the

Paul Ehrlich Institute The Paul Ehrlich Institute (German: ''Paul-Ehrlich-Institut – Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel'', PEI) is a German federal agency, medical regulatory body and research institution for vaccines and biomedicines. It ...

(PEI). He is also professor of biochemistry at the

Goethe University Frankfurt Goethe University (german: link=no, Johann Wolfgang Goethe-Universität Frankfurt am Main) is a university located in Frankfurt am Main, Germany. It was founded in 1914 as a citizens' university, which means it was founded and funded by the wealt ...

Early life and education

Cichutek completed his studies of chemistry in 1981 and earned a doctoral degree in biochemistry in 1984, both at the University of Münster.

Career

From 1985 to 1988 Cichutek was affiliated with the Department of Molecular Biology and Virus Laboratory at the

University of California, Berkeley The University of California, Berkeley (UC Berkeley, Berkeley, Cal, or California) is a public land-grant research university in Berkeley, California. Established in 1868 as the University of California, it is the state's first land-grant u ...

. He has been employed by the Paul Ehrlich Institute since 1988; he became the institute's vice president in 1999 and its president in 2009. In addition to his role at PEI, Cichutek chaired the Bundesärztekammer's commission on

somatic gene therapy Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. The first attempt at modifying human DN ...

from 2000 to 2010, and the Gene Therapy Working Party of the

European Medicines Agency The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or Euro ...

(EMA) from 2003 to 2010. Since 2020, he has been an ex-officio member of a working group on

COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ...

s established by the

Strategic Advisory Group of Experts The Strategic Advisory Group of Experts (SAGE) is the principal advisory group to World Health Organization (WHO) for vaccines and immunization. Established in 1999 through the merging of two previous committees, notably the Scientific Advisory Grou ...

at the

World Health Organization The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. The WHO Constitution states its main objective as "the attainment by all peoples of the highest possible level of h ...

(WHO).SAGE Working Group on Covid-19 vaccines

(WHO).

Bibliography

* ''SIV grows unchanged in human cells''. Werner A, Baier M, Cichutek K, Kurth R. Nature. 1990 Mar 8; 344(6262):113. DOI:10.1038/344113a0 * ''Development of a quasispecies of human immunodeficiency virus type 1 in vivo''. Cichutek K, Merget H, Norley S, Linde R, Kreuz W, Gahr M, Kurth R. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7365-9. * ''Lack of immune suppression in SIV-infected natural hosts''. Cichutek K, Norley S. AIDS. 1993; 7 Suppl 1:S25-35. Review. * ''Development of transforming function during transduction of proto-ras into Harvey sarcoma virus''. Lang M, Treinies I, Duesberg PH, Kurth R, Cichutek K. Proc Natl Acad Sci U S A. 1994 Jan 18; 91(2):654-8. * ''Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells''. Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstädter M, Kurth R, Groner B, Cichutek K. Proc Natl Acad Sci U S A. 1997 Aug 5; 94(16):8640-5. * ''The U3 promoter and the nef gene of simian immunodeficiency virus (SIV) smmPBj1.9 do not confer acute pathogenicity upon SIVagm''. Wagener S, Dittmar MT, Beer B, König R, Plesker R, Norley S, Kurth R, Cichutek K. J Virol. 1998 Apr; 72(4):3446-50. * ''Retroviral cell targeting vectors''. Buchholz CJ, Stitz J, Cichutek K. Curr Opin Mol Ther. 1999 Oct; 1(5):613-21. Review. * ''European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements''. Robertson JS, Cichutek K. Dev Biol (Basel). 2000; 104:53-6. * ''A novel lentivirus vector derived from apathogenic simian immunodeficiency virus''. Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K. Virology. 2001 Dec 20; 291(2):191-7. DOI:10.1006/viro.2001.1183 * ''Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR''. Sun Y, Song M, Jäger E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K. Clin Cancer Res. 2008 Jul 1; 14(13):4306-15. doi:10.1158/1078-0432.CCR-07-4849. * ''Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?'' Buchholz CJ, Mühlebach MD, Cichutek K. Trends Biotechnol. 2009 May; 27(5):259-65. doi:10.1016/j.tibtech.2009.02.002. Epub 2009 Mar 25. Review. * ''Adherens junction protein nectin-4 is the epithelial receptor for measles virus''. Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB Jr, Cichutek K, von Messling V, Lopez M, Cattaneo R. Nature. 2011 Nov 2;480(7378):530-3. doi:10.1038/nature10639. * ''A global regulatory science agenda for vaccines''. Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D. Vaccine. 2013 Apr 18; 31 Suppl 2:B163-75. doi:10.1016/j.vaccine.2012.10.117. Review * ''DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety''. Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD. Mol Ther. 2013 Apr; 21(4):849-59. doi:10.1038/mt.2013.16. Epub 2013 Feb 5. * ''Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine''. Müller-Berghaus J, Volkers P, Scherer J, Cichutek K.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1538-44. doi:10.1007/s00103-013-1826-y. German * ''A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform''. Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J,Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.J Virol. 2015 Nov; 89(22):11654-67. doi:10.1128/JVI.01815-15. Epub 2015 Sep 9. * ''Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors''. Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD. Mol Ther Oncolytics. 2016 Feb 24; 3:16003. doi:10.1038/mto.2016.3 eCollection 2016.

References

{{DEFAULTSORT:Cichutek, Klaus German biochemists Paul Ehrlich Institute people Goethe University Frankfurt faculty 1956 births People from Recklinghausen Living people